Newsmeme!
Discover News you didn't know existed
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the publication of detailed 48-week data from two Phase III pivotal clinical trials evaluating the safety and efficacy of its once-daily Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection in adults.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the publication of detailed 48-week data from two Phase III pivotal clinical trials evaluating the safety and efficacy of its once-daily Viread ® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection in adults. The results of both studies (Studies 102 and 103), published in the December 4, 2008 issue ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the publication of detailed 48-week data from ...
It's hard to believe, but December 1, 2008 marks the 20th anniversary of World AIDS Day. Today we come together as friends and family, as a city, as a state, as a country, and (most importantly) as a global community to educate and inform on the world AIDS epidemic. While others will (and should) debate the politics of this crisis, we here at the ScientIST feel it’s our duty to share some ...
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |